{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:36:20Z","timestamp":1791844580397,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":883,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (NSFC)","doi-asserted-by":"publisher","award":["81630061"],"award-info":[{"award-number":["81630061"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (NSFC)","doi-asserted-by":"publisher","award":["81473255"],"award-info":[{"award-number":["81473255"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (NSFC)","doi-asserted-by":"publisher","award":["81673484"],"award-info":[{"award-number":["81673484"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2017-I2M-1\u2013014"],"award-info":[{"award-number":["2017-I2M-1\u2013014"]}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1074\/jbc.ra118.001729","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T20:40:10Z","timestamp":1518036010000},"page":"5323-5334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus"],"prefix":"10.1016","volume":"293","author":[{"given":"Yuanmei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1074\/jbc.RA118.001729_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrm1076","article-title":"The structural biology of type I viral membrane fusion","volume":"4","author":"Colman","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"10.1074\/jbc.RA118.001729_bib2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1146\/annurev.biochem.70.1.777","article-title":"Mechanisms of viral membrane fusion and its inhibition","volume":"70","author":"Eckert","year":"2001","journal-title":"Annu. Rev. Biochem"},{"key":"10.1074\/jbc.RA118.001729_bib3","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1073\/pnas.92.11.4867","article-title":"SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4\u2212 cells by two distinct mechanisms","volume":"92","author":"Yahi","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.RA118.001729_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","article-title":"Core structure of gp41 from the HIV envelope glycoprotein","volume":"89","author":"Chan","year":"1997","journal-title":"Cell"},{"key":"10.1074\/jbc.RA118.001729_bib5","doi-asserted-by":"crossref","first-page":"12303","DOI":"10.1073\/pnas.94.23.12303","article-title":"Atomic structure of a thermostable subdomain of HIV-1 gp41","volume":"94","author":"Tan","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.RA118.001729_bib6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/387426a0","article-title":"Atomic structure of the ectodomain from HIV-1 gp41","volume":"387","author":"Weissenhorn","year":"1997","journal-title":"Nature"},{"key":"10.1074\/jbc.RA118.001729_bib7","doi-asserted-by":"crossref","first-page":"15613","DOI":"10.1073\/pnas.95.26.15613","article-title":"Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target","volume":"95","author":"Chan","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.RA118.001729_bib8","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/QAD.0000000000000683","article-title":"Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target","volume":"29","author":"Qiu","year":"2015","journal-title":"AIDS"},{"key":"10.1074\/jbc.RA118.001729_bib9","doi-asserted-by":"crossref","first-page":"18207","DOI":"10.1073\/pnas.1413592112","article-title":"Single-chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV-1 drugs","volume":"111","author":"Crespillo","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.RA118.001729_bib10","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1016\/j.bmcl.2013.07.026","article-title":"Identification of fragments targeting an alternative pocket on HIV-1 gp41 by NMR screening and similarity searching","volume":"23","author":"Chu","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1074\/jbc.RA118.001729_bib11","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0092-8674(00)81430-0","article-title":"HIV entry and its inhibition","volume":"93","author":"Chan","year":"1998","journal-title":"Cell"},{"key":"10.1074\/jbc.RA118.001729_bib12","doi-asserted-by":"crossref","first-page":"9676","DOI":"10.1128\/JVI.72.12.9676-9682.1998","article-title":"Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41","volume":"72","author":"Weng","year":"1998","journal-title":"J. Virol"},{"key":"10.1074\/jbc.RA118.001729_bib13","doi-asserted-by":"crossref","first-page":"9770","DOI":"10.1073\/pnas.91.21.9770","article-title":"Peptides corresponding to a predictive \u03b1-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection","volume":"91","author":"Wild","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.RA118.001729_bib14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/aid.1993.9.1051","article-title":"A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion","volume":"9","author":"Wild","year":"1993","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1074\/jbc.RA118.001729_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/365113a0","article-title":"HIV-1 inhibition by a peptide","volume":"365","author":"Jiang","year":"1993","journal-title":"Nature"},{"key":"10.1074\/jbc.RA118.001729_bib16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nsb0498-276","article-title":"Capture of an early fusion-active conformation of HIV-1 gp41","volume":"5","author":"Furuta","year":"1998","journal-title":"Nat. Struct. Biol"},{"key":"10.1074\/jbc.RA118.001729_bib17","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.2174\/1381612811319100004","article-title":"Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion","volume":"19","author":"He","year":"2013","journal-title":"Curr. Pharm. Des"},{"key":"10.1074\/jbc.RA118.001729_bib18","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.2174\/138161210794079218","article-title":"Inhibition of HIV-1 by fusion inhibitors","volume":"16","author":"Eggink","year":"2010","journal-title":"Curr. Pharm. Des"},{"key":"10.1074\/jbc.RA118.001729_bib19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/JVI.72.2.986-993.1998","article-title":"Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides","volume":"72","author":"Rimsky","year":"1998","journal-title":"J. Virol"},{"key":"10.1074\/jbc.RA118.001729_bib20","doi-asserted-by":"crossref","first-page":"12428","DOI":"10.1128\/JVI.78.22.12428-12437.2004","article-title":"Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor","volume":"78","author":"Baldwin","year":"2004","journal-title":"J. Virol"},{"key":"10.1074\/jbc.RA118.001729_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/dkh330","article-title":"Resistance to enfuvirtide, the first HIV fusion inhibitor","volume":"54","author":"Greenberg","year":"2004","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1074\/jbc.RA118.001729_bib22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2012.01.002","article-title":"Is there a future for antiviral fusion inhibitors?","volume":"2","author":"Berkhout","year":"2012","journal-title":"Curr. Opin. Virol"},{"key":"10.1074\/jbc.RA118.001729_bib23","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1128\/AAC.49.3.1113-1119.2005","article-title":"Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41","volume":"49","author":"Xu","year":"2005","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1074\/jbc.RA118.001729_bib24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350400900115","article-title":"Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis","volume":"9","author":"Witvrouw","year":"2004","journal-title":"Antivir. Ther"},{"key":"10.1074\/jbc.RA118.001729_bib25","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/QAD.0b013e32835edc1d","article-title":"An ancestral HIV-2\/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity","volume":"27","author":"Borrego","year":"2013","journal-title":"AIDS"},{"key":"10.1074\/jbc.RA118.001729_bib26","doi-asserted-by":"crossref","first-page":"e01839","DOI":"10.1128\/JVI.01839-16","article-title":"A helical short-peptide fusion inhibitor with highly potent activity against human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus","volume":"91","author":"Xiong","year":"2017","journal-title":"J. Virol"},{"key":"10.1074\/jbc.RA118.001729_bib27","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.tim.2008.09.003","article-title":"HIV-2: the forgotten AIDS virus","volume":"16","author":"de Silva","year":"2008","journal-title":"Trends Microbiol"},{"key":"10.1074\/jbc.RA118.001729_bib28","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/427993","article-title":"T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen","volume":"191","author":"Lalezari","year":"2005","journal-title":"J. Infect. Dis"},{"key":"10.1074\/jbc.RA118.001729_bib29","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1086\/381707","article-title":"Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV","volume":"189","author":"Eron","year":"2004","journal-title":"J. Infect. Dis"},{"key":"10.1074\/jbc.RA118.001729_bib30","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.1128\/JVI.00352-08","article-title":"Selection of T1249-resistant human immunodeficiency virus type 1 variants","volume":"82","author":"Eggink","year":"2008","journal-title":"J. Virol"},{"key":"10.1074\/jbc.RA118.001729_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3851\/IMP2031","article-title":"Novel agents for the treatment of HIV-2 infection","volume":"17","author":"Peterson","year":"2012","journal-title":"Antiviral Ther"},{"key":"10.1074\/jbc.RA118.001729_bib32","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1128\/JVI.75.6.3038-3042.2001","article-title":"Membrane-anchored peptide inhibits human immunodeficiency virus entry","volume":"75","author":"Hildinger","year":"2001","journal-title":"J. Virol"},{"key":"10.1074\/jbc.RA118.001729_bib33","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1128\/JVI.78.2.568-575.2004","article-title":"Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides","volume":"78","author":"Egelhofer","year":"2004","journal-title":"J. Virol"},{"key":"10.1074\/jbc.RA118.001729_bib34","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1073\/pnas.0901007106","article-title":"Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency","volume":"106","author":"Ingallinella","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.RA118.001729_bib35","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/jac\/dkt529","article-title":"Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure","volume":"69","author":"Augusto","year":"2014","journal-title":"J. Antimicrobial Chemother"},{"key":"10.1074\/jbc.RA118.001729_bib36","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/QAD.0000000000001073","article-title":"Development of potent and long-acting HIV-1 fusion inhibitors","volume":"30","author":"Chong","year":"2016","journal-title":"AIDS"},{"key":"10.1074\/jbc.RA118.001729_bib37","doi-asserted-by":"crossref","first-page":"e00288","DOI":"10.1128\/JVI.00288-17","article-title":"A lipopeptide HIV-1\/2 fusion inhibitor with highly potent in vitro, ex vivo, and in vivo antiviral activity","volume":"91","author":"Chong","year":"2017","journal-title":"J. Virol"},{"key":"10.1074\/jbc.RA118.001729_bib38","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1096\/fj.12-215111","article-title":"Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1","volume":"26","author":"Ashkenazi","year":"2012","journal-title":"FASEB J"},{"key":"10.1074\/jbc.RA118.001729_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000509","article-title":"Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action","volume":"5","author":"Wexler-Cohen","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1074\/jbc.RA118.001729_bib40","doi-asserted-by":"crossref","first-page":"e00831","DOI":"10.1128\/JVI.00831-17","article-title":"Enfuvirtide (T20)-based lipopeptide is a potent HIV-1 cell fusion inhibitor: implication for viral entry and inhibition","volume":"91","author":"Ding","year":"2017","journal-title":"J. Virol"},{"key":"10.1074\/jbc.RA118.001729_bib41","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1128\/JVI.02853-13","article-title":"Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"88","author":"deCamp","year":"2014","journal-title":"J. Virol"},{"key":"10.1074\/jbc.RA118.001729_bib42","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1128\/JVI.00168-09","article-title":"Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains","volume":"83","author":"Pan","year":"2009","journal-title":"J. Virol"},{"key":"10.1074\/jbc.RA118.001729_bib43","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2174\/138161210790963751","article-title":"Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins","volume":"16","author":"Steffen","year":"2010","journal-title":"Curr. Pharm. Des"},{"key":"10.1074\/jbc.RA118.001729_bib44","doi-asserted-by":"crossref","first-page":"12772","DOI":"10.1073\/pnas.0701478104","article-title":"Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus","volume":"104","author":"Dwyer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.RA118.001729_bib45","doi-asserted-by":"crossref","first-page":"11126","DOI":"10.1074\/jbc.M800200200","article-title":"Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor","volume":"283","author":"He","year":"2008","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.RA118.001729_bib46","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J","article-title":"Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells","volume":"41","author":"Otaka","year":"2002","journal-title":"Angew. Chem. Int. Ed. Engl"},{"key":"10.1074\/jbc.RA118.001729_bib47","doi-asserted-by":"crossref","first-page":"16332","DOI":"10.1073\/pnas.0807335105","article-title":"Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains","volume":"105","author":"He","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.RA118.001729_bib48","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1096\/fj.12-222547","article-title":"Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1","volume":"27","author":"Chong","year":"2013","journal-title":"FASEB J"},{"key":"10.1074\/jbc.RA118.001729_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/QAD.0000000000000498","article-title":"Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket","volume":"29","author":"Chong","year":"2015","journal-title":"AIDS"},{"key":"10.1074\/jbc.RA118.001729_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032599","article-title":"Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor","volume":"7","author":"Chong","year":"2012","journal-title":"PLoS One"},{"key":"10.1074\/jbc.RA118.001729_bib51","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/protein\/gzs051","article-title":"Generation of a dual-functional split-reporter protein for monitoring membrane fusion using self-associating split GFP","volume":"25","author":"Ishikawa","year":"2012","journal-title":"Protein Eng. Des. Sel"},{"key":"10.1074\/jbc.RA118.001729_bib52","doi-asserted-by":"crossref","first-page":"14681","DOI":"10.1074\/jbc.M109.067090","article-title":"Conformational changes of the HIV-1 envelope protein during membrane fusion are inhibited by the replacement of its membrane-spanning domain","volume":"285","author":"Kondo","year":"2010","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.RA118.001729_bib53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul"},{"key":"10.1074\/jbc.RA118.001729_bib54","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev"},{"key":"10.1074\/jbc.RA118.001729_bib55","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode","volume":"276","author":"Otwinowski","year":"1997","journal-title":"Methods Enzymol"},{"key":"10.1074\/jbc.RA118.001729_bib56","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr"},{"key":"10.1074\/jbc.RA118.001729_bib57","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr"},{"key":"10.1074\/jbc.RA118.001729_bib58","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1107\/S0907444902016657","article-title":"PHENIX: building new software for automated crystallographic structure determination","volume":"58","author":"Adams","year":"2002","journal-title":"Acta Crystallogr. D Biol. Crystallogr"},{"key":"10.1074\/jbc.RA118.001729_bib59","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1107\/S0021889892009944","article-title":"PROCHECK: a program to check the stereochemical quality of protein structures","volume":"26","author":"Laskowski","year":"1993","journal-title":"J. Appl. Crystallogr"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820410038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820410038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/jbc.RA118.001729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T01:31:22Z","timestamp":1660440682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925820410038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":59,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0021925820410038"],"URL":"https:\/\/doi.org\/10.1074\/jbc.ra118.001729","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1074\/jbc.RA118.001729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Zhu et al.","name":"copyright","label":"Copyright"}]}}